Apogenix
Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, based either on the targeted modulation of apoptosis (programmed cell death) or on a blockade of the invasive growth of tumour cells.
The lead product candidate of the company, APG101, entered a controlled Phase II proof-of-concept study with glioblastoma patients in December 2009.
Product Pipeline
| Product | Compound | Indication | Pre-clinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
| CD95L Blocker | APG101 | Glioblastoma | completed | completed | 25% completed | - |
| CD95L Blocker | APG101 | aGvHD | completed | completed | - | - |
| IL-4 blocker | Various | Solid tumours | 30% completed | - | - | - |
Partnering
Apogenix has built a portfolio of first-in-class molecules ready for partnering activities. The partnering process for APG101 has been initiated recently. Apogenix is looking for a strategic alliance with a fully committed partner for late-stage clinical development and commercialisation.